Aurobindo Pharma Ltd vs Sun Pharmaceuticals Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Apr 03, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1335 as of 02 Apr 15:30 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 49.4 on March 2021 to 38.1 on March 2025 . This represents a CAGR of -5.06% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 143384 crore on March 2021 to ₹ 416392 crore on March 2025 . This represents a CAGR of 23.77% over 5 years The revenue of Aurobindo Pharma Ltd for the Dec '25 is ₹ 8833 crore as compare to the Sep '25 revenue of ₹ 8407 crore. This represent the growth of 5.07% The revenue of Sun Pharmaceutical Industries Ltd for the Dec '25 is ₹ 16099 crore as compare to the Sep '25 revenue of ₹ 14948 crore. This represent the growth of 7.7% The ebitda of Aurobindo Pharma Ltd for the Dec '25 is ₹ 1896 crore as compare to the Sep '25 ebitda of ₹ 1800 crore. This represent the growth of 5.31% The ebitda of Sun Pharmaceutical Industries Ltd for the Dec '25 is ₹ 5037 crore as compare to the Sep '25 ebitda of ₹ 4996 crore. This represent the growth of 0.82% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 909.8 crore over 7 quarters. This represents a CAGR of -0.53% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2871 crore to ₹ 3401 crore over 7 quarters. This represents a CAGR of 10.16% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 213.61 % on March 2021 to 89.64 % on March 2025 . This represents a CAGR of -15.94% over 5 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

FAQs for the comparison of Aurobindo Pharma Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Aurobindo Pharma Ltd is 77,592 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 406,603 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Aurobindo Pharma Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Sun Pharmaceutical Industries Ltd?

As of April 3, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1335.95. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1694.65.

How do dividend payouts of Aurobindo Pharma Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.